In recent years, GLP-1 receptor agonist drugs have established themselves in both scientific and public debate as an effective solution for the treatment of diabetes and obesity. Their efficacy is now well documented, to the point that more and more people are approaching these therapies with high expectations.

However, there is one aspect that cannot be overlooked, namely the management of the rebound effect. In other words: what happens when GLP-1 treatment is discontinued? This is a question that arises not only from curiosity, but also from the direct experience of those who have stopped the therapy or are considering doing so.

The key issue is to better understand the long-term efficacy of GLP-1 drugs, because while weight loss during treatment can be significant, it is in the subsequent phase that the real stability of the result is determined.

GLP-1: how the drugs work and what happens when treatment is stopped

GLP-1 receptor agonist drugs work by mimicking the action of a gut hormone involved in regulating appetite and metabolism. This mechanism allows them to reduce hunger, slow gastric emptying and improve glycaemic control, creating favourable conditions for weight loss during treatment.1

But why is there so much focus on discontinuing GLP-1 therapy? Because their effectiveness depends on continuous administration. The drug does not permanently alter the biological mechanisms underlying obesity or diabetes, but rather modulates them temporarily.

When treatment is discontinued, the body gradually tends to return to its previous balance. The effect on satiety diminishes over a few weeks, and the body begins to send stronger hunger signals again, while glycaemic control may also become less stable, particularly in patients with diabetes.2

This happens because the body reacts to weight loss and the absence of the drug by activating biological mechanisms: leptin (the satiety hormone) decreases and ghrelin (the hunger hormone) increases, encouraging greater food intake. While the drug is being taken, hunger is regulated at a central (brain) level, but this effect disappears once treatment stops. In addition to weight, blood glucose levels are also affected: without the drug, the body loses key support mechanisms involved in insulin regulation and gastric emptying, making post-meal glucose control significantly more difficult.3

In practice, the effectiveness of GLP-1 drugs during treatment does not automatically translate into long-term stability of results after discontinuation.

Rebound risk: effects on weight and blood sugar control

One of the most relevant aspects following treatment discontinuation is the so-called rebound risk. This is a well-documented phenomenon: after stopping therapy, lost weight tends to be regained progressively and often significantly. Within one year (54 weeks), the improvements achieved tend to almost completely disappear.4

Clinical studies have shown that patients may regain around two-thirds of the weight lost within one year of discontinuation. Participants in a study published in Diabetes, Obesity and Metabolism, one year after stopping both weekly semaglutide (2.4 mg) and a lifestyle intervention programme, regained two-thirds of the weight they had lost, alongside a similar deterioration in cardiometabolic parameters.5

At the same time, there is a reduction in glycaemic control following discontinuation of GLP-1 drugs. In diabetic patients, this may result in increased blood glucose levels and the loss of benefits achieved during treatment, as will be explored further below.

Side effects associated with discontinuation of GLP-1 drugs

Alongside the side effects of Ozempic and, more broadly, the side effects of GLP-1 drugs during treatment, it is also essential to consider the effects of discontinuation. As anticipated, stopping therapy triggers a series of changes affecting appetite, metabolism and body weight.6

These effects arise because the drug ceases to modulate the biological signals it had temporarily regulated. The result is a gradual return to previous conditions, often accompanied by a more intense perception of symptoms.

Return of appetite and food noise

One of the most immediate effects is the return of appetite after GLP-1, often perceived as sudden and difficult to manage.

This is the so-called food noise, referring to constant thoughts about food and the urge to eat. This mechanism is not purely psychological, but linked to neurobiological pathways that become active again in the absence of the drug.7

In terms of valence (pleasure) and arousal (motivation), GLP-1 reduces the excitement or urgency triggered by food cues, while enhancing the positive valence of actual food consumption, thereby signalling satiety to the brain. Neuroimaging studies have revealed the mechanisms underlying the reduction in compulsive craving during GLP-1 therapy.8

Animal research provides further evidence at a cellular level. Alhadeff et al. (2012) demonstrated that GLP-1-producing neurons in the brainstem project directly to the ventral tegmental area and nucleus accumbens, key regions of the dopaminergic reward pathway. When researchers activated GLP-1 in these circuits, rodents lost interest in high-fat foods; when it was blocked, they overate.9

Loss of glycaemic control

Another critical aspect concerns the reduction in glycaemic control following discontinuation of GLP-1 drugs. These medications improve insulin response and stabilise blood glucose levels during treatment.

When treatment is stopped, this balance is disrupted. Theoretical models suggest that blood glucose, blood pressure and lipid levels return to baseline within approximately one year, while glycated haemoglobin (HbA1c) returns to pre-treatment levels within 12 to 18 months. Early discontinuation (within one year) is also associated with an increased risk of coronary artery disease and heart failure compared to continued therapy.10

In summary, GLP-1 treatment for obesity and diabetes does not permanently address the underlying causes of the condition, but requires ongoing management to sustain results.

Increased cardiovascular risk

Based on evidence from the study by Piccinini, Favacchio and Panico (2023), discontinuation of GLP-1 receptor agonist therapy leads to a significant increase in the risk of major adverse cardiovascular events (MACE), including myocardial infarction and non-fatal stroke.

Data analysis shows that discontinuation profoundly alters the Hazard Ratio, effectively tripling the risk (3.40-fold increase) in primary prevention patients and increasing it 2.71-fold in secondary prevention patients with a prior clinical history.

These findings highlight the time-dependent nature of the cardiovascular protection offered by these drugs: the clinical benefit is not permanent but appears to persist only as long as the patient remains exposed to the active compound over time, diminishing rapidly once treatment is stopped.11

How to manage discontinuation of GLP-1 drugs: practical tips

In summary, discontinuing GLP-1 drugs represents a clinically delicate phase that requires a structured approach. Without a strategy, there is a high risk of rapidly losing the benefits achieved during treatment, both in terms of weight and metabolic control.

Alongside pharmacological management, working on metabolism becomes essential. Adequate protein intake, together with physical activity—particularly resistance training—helps preserve muscle mass and maintain energy expenditure.

Diet also plays a key role. Structuring meals throughout the day and favouring minimally processed foods helps manage the return of appetite, especially in the early stages after discontinuation. At the same time, regular monitoring of weight and metabolic parameters allows for early intervention in case of changes.

It is precisely in managing this phase that the need for a broader approach emerges. Companies such as Cor.Con. International operate in this direction, developing metabolic system supplements designed to support the body during and after GLP-1 therapy. In a context where the drug acts on complex but temporary mechanisms, nutritional support becomes a strategic element for reducing side effects and improving the sustainability of results.

Discontinuation, therefore, does not represent the end of the journey, but a critical transition that must be managed as effectively as possible.

  1. humanitas.it ↩︎
  2. Tzang C, Wu P, Luo C et al., Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis, eClinicalMedicine, 2025; 90 ↩︎
  3. Tzang C, Wu P, Luo C et al., Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis, eClinicalMedicine, 2025; 90 ↩︎
  4. Tzang C, Wu P, Luo C et al., Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis, eClinicalMedicine, 2025; 90 ↩︎
  5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725  ↩︎
  6. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine | Volume 31 | March 2025 | 951–962 ↩︎
  7. Cook, G. (2026). Quieting “food noise”: How GLP-1s and mindfulness rewire the default mode network (DMN) and reward circuits. Cureus, 18(1), e100818. https://doi.org/10.7759/cureus.100818 ↩︎
  8. Cook, G. (2026). Quieting “food noise”: How GLP-1s and mindfulness rewire the default mode network (DMN) and reward circuits. Cureus, 18(1), e100818. https://doi.org/10.7759/cureus.100818 ↩︎
  9. Amber L. Alhadeff, Laura E. Rupprecht, Matthew R. Hayes, GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake, Endocrinology, Volume 153, Issue 2, 1 February 2012, Pages 647–658, https://doi.org/10.1210/en.2011-1443 ↩︎
  10. E.Shah, R.AlShiab, A.Abdo, L.Ozbek, A.Covic, and M.Kanbay, “Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists,” Diabetes, Obesity and Metabolism (2026): 1–13, https://doi.org/10.1111/dom.70713. ↩︎
  11. Piccini S, Favacchio G, Panico C, et al. Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. Cardiovasc Diabetol 2023, 22: 69. ↩︎